What is the role of sildenafil in a patient with pulmonary hypertension secondary to atrial fibrillation?

Sildenafil is NOT recommended for pulmonary hypertension secondary to atrial fibrillation

Sildenafil should not be used in patients with pulmonary hypertension due to atrial fibrillation, as this represents Group 2 PH (left heart disease), where PAH-specific therapies are contraindicated. The primary treatment must focus on optimizing management of the underlying atrial fibrillation and any associated left heart dysfunction 1, 2.

Understanding the Clinical Context

Atrial fibrillation causes pulmonary hypertension through elevated left atrial pressures that transmit backward into the pulmonary circulation. This is fundamentally different from pulmonary arterial hypertension (PAH, WHO Group 1), where sildenafil is indicated 3.

Key distinction: PH from atrial fibrillation is classified as WHO Group 2 (PH due to left heart disease), not Group 1 (PAH). This classification is critical because it determines whether PAH-specific drugs like sildenafil are appropriate.

Why Sildenafil is Contraindicated

Evidence Against Use

The 2009 ESC/ERS guidelines explicitly state: "The use of PAH specific drug therapy is not recommended in patients with PH due to left heart disease" 1, 2. This recommendation carries a Class III designation (meaning harm may result).

The rationale is compelling:

• Randomized controlled trials of epoprostenol and bosentan in advanced heart failure were terminated early due to increased adverse events in the treatment groups 1, 2
• While one small study suggested sildenafil might improve exercise capacity in left heart disease-associated PH, the guidelines emphasize that "the history of medical therapy for heart failure is full of examples where drugs had positive effects on surrogate endpoints but eventually turned out to be detrimental" 1, 2
• Phosphodiesterase type-3 inhibitors serve as a cautionary example of this phenomenon 1, 2

Pathophysiologic Concerns

Sildenafil works by reducing pulmonary vascular resistance through vasodilation 3. In left heart disease:

• Lowering pulmonary vascular resistance increases blood flow back to an already dysfunctional left heart
• This can worsen pulmonary venous congestion and precipitate pulmonary edema
• The elevated left-sided filling pressures are the primary problem, not intrinsic pulmonary vascular disease

The Correct Treatment Approach

Primary Management Strategy

Focus on treating the atrial fibrillation and optimizing left heart function 1, 2:

1. Rate or rhythm control of atrial fibrillation
2. Anticoagulation as indicated
3. Diuretics to reduce left-sided filling pressures
4. Standard heart failure medications (ACE inhibitors, beta-blockers, etc.) if left ventricular dysfunction is present
5. Consider cardioversion if rhythm control strategy is chosen

Diagnostic Confirmation Required

Before definitively excluding sildenafil, confirm the diagnosis:

• Right heart catheterization may be needed to measure pulmonary capillary wedge pressure (PCWP)
• PCWP >15 mmHg confirms Group 2 PH (left heart disease) 1, 2
• Echocardiographic features suggesting elevated left ventricular filling pressures include: left atrial enlargement, concentric LV remodeling, LV hypertrophy 1

The "Out of Proportion" Exception

There is one narrow scenario where sildenafil might be considered:

If the patient has "out of proportion" PH (defined as transpulmonary gradient >12 mmHg despite elevated wedge pressure), they should ideally be enrolled in clinical trials rather than receiving off-label PAH therapy 1, 2. This represents a mixed picture where intrinsic pulmonary vascular disease coexists with left heart disease.

However, routine use outside of clinical trials remains not recommended 1, 2.

Critical Pitfalls to Avoid

• Do not assume all PH is PAH - the etiology determines treatment
• Do not use sildenafil based solely on elevated pulmonary pressures without determining the underlying cause
• Do not extrapolate PAH trial data (where sildenafil is effective 4, 5, 6) to left heart disease-associated PH
• Recognize that improving exercise capacity or hemodynamics does not equal improved mortality - this was the lesson from phosphodiesterase-3 inhibitors in heart failure

When Sildenafil IS Appropriate

For context, sildenafil is indicated for:

• WHO Group 1 PAH (idiopathic, connective tissue disease-associated, congenital heart disease with left-to-right shunts) 4, 3
• Chronic thromboembolic PH in selected cases 5
• Dosing: 20 mg three times daily, with potential titration to 80 mg TID if inadequate response 4, 7

The recent ASSET-1 trial confirmed that 80 mg TID is safe and more effective than lower doses in true PAH 7, but this does not change the contraindication in left heart disease.